secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2022-10-05T23:59:59+00:00
Accession:  0001493152-22-027728
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sigyn Therapeutics appoints Jim Dorst, Richa Nand, and Christopher Wetzel to Board
--------------------------------------------------------------------------------

- Appointments effective October 10, 2022; each director brings distinct expertise.
- Jim Dorst: 30+ years finance/operations; former Director of Corporate Development at SYNNEX/Concentrix and CFO of Aethlon Medical.
- Richa Nand: IP attorney and founder of Insight Patents; biomedical researcher background at Cedars Sinai.
- Christopher Wetzel: CEO of Surgery Center at Hamilton since 2004; long-term investor in extracorporeal therapy.
- Board cited each director's experience in financial expertise, IP, or healthcare delivery as qualification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-027728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer